Technology area: Biotechnology & Pharmaceuticals
64 pending office actions • 36 clients • 61 examiners • 44 art units • 0 of 64 (0%) have an AI response strategy ready
Raphael Bellum PLLC focuses on Biotechnology & Pharmaceuticals and has 64 pending office actions. Its reported career application volume is 2051, with an 80.06% resolved allowance rate and an average of 3.59 office actions per allowance.
The allowance rate indicates that most resolved applications reached allowance, while the office-action average shows that allowed matters commonly required several examination responses. Together, the measures describe a portfolio in which allowance was often achieved through continued prosecution rather than through minimal examination activity.
The pending docket is part of a substantial historical application base. Biotechnology practitioners can use the data to anticipate the importance of response planning and claim support, while recognizing that the aggregate record does not disclose the specific biological technologies or outstanding issues in the pending cases.
Based on the USPTO statutory response window for each pending office action. 20 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 20 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 11 (17%) |
| §103 only | 14 (22%) |
| §102 only | 2 (3%) |
| §112 only | 11 (17%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 5 (8%) |
| Multi-statute (no §101) | 19 (30%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, ERIC | 2 | 69.8% | +19.4% |
| JONES, CHRISTOPHER P | 2 | 76.1% | +24.8% |
| VIVLEMORE, TRACY ANN | 2 | 73.0% | +6.4% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +39.1% |
| MORAN, KATHERINE M | 1 | 54.3% | +24.2% |
| QUAIM, LAMIA | 1 | 74.6% | +17.5% |
| MCCLURE, CHRISTINA D | 1 | 29.9% | +33.1% |
| WALKER, CHRISTOPHER RICHARD | 1 | 73.0% | +18.0% |
| GOODMAN, MATTHEW PARKER | 1 | 20.2% | +30.3% |
| ANDERSON, JAMES D | 1 | 55.1% | +19.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18352677 | COMPOSITIONS CONTAINING KRATOM COMPOUNDS | SPAINE, ROBERT FRANKLIN | 441d overdue |
| 18696645 | AUTONOMOUS ROBOT PLATFORM FOR PEST IDENTIFICATION AND CONTROL | AWORUNSE, OLUWABUSAYO ADEBANJO | 146d overdue |
| 16456773 | RNA VIRUSES EXPRESSING IL-12 FOR IMMUNOVIROTHERAPY | VIVLEMORE, TRACY ANN | 98d overdue |
| 18858080 | CRYSTALLINE QUATERNARY SALTS OF 4-SUBSTITUTED TRYPTAMINES | ANDERSON, JAMES D | 44d overdue |
| 17747557 | MEASLES VIRUS ENCODING A TUMOR ANTIGEN | NOBLE, MARCIA STEPHENS | 44d overdue |
| 18257639 | AMANITA MUSCARIA COMPOUNDS | HOFFMAN, SUSAN COE | 32d overdue |
| 18265286 | 3-CYCLIC AMINE-INDOLE DERIVATIVES AS SEROTONERGIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | LEE, CHIHYI NMN | 26d overdue |
| 18299857 | STATIC MAGNETIC FIELD GENERATOR FOR TREATMENT OF CANCER | LANDEEN, BROGAN RANE | 2d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19189953 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TRAN, ERIC | 44d overdue |
| 18858080 | CRYSTALLINE QUATERNARY SALTS OF 4-SUBSTITUTED TRYPTAMINES | ANDERSON, JAMES D | 44d overdue |
| 19568483 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
| 19413522 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TRAN, ERIC | — |
| 19407334 | REINFORCED SLIDING MITT INCLUDING PROTECTION GUARD WITH TREAD FOR BASEBALL AND SOFTBALL | MORAN, KATHERINE M | — |
| 19252210 | COMPUTER-IMPLEMENTED METHOD FOR IDENTIFYING THE POSITION OF A HOLE OR A CRACK IN A DRILL STRING AND COMPUTER-READABLE STORAGE MATERIAL | QUAIM, LAMIA | — |
| 19181025 | HIGH TEMPERATURE CORROSION RESISTANT ORGANIC-INORGANIC HYBRID COATINGS | MCCLURE, CHRISTINA D | — |
| 19047044 | SEMq System for Identification, Determination, Characterization, and/or Quantification of Groundwater or Aquifers | WALKER, CHRISTOPHER RICHARD | — |
| Art Unit | Apps |
|---|---|
| 1629 | 4 |
| 1625 | 4 |
| 1622 | 3 |
| 3791 | 3 |
| 1776 | 2 |
| 1616 | 2 |
| 1626 | 2 |
| 1691 | 2 |
| 1621 | 2 |
| 1619 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19568483 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103 | Final Rejection | — | Pending | Mar 16, 2026 |
| 19413522 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. | TRAN, ERIC | 1629 | §102§112 | Non-Final OA | — | Pending | Dec 09, 2025 |
| 19407334 | REINFORCED SLIDING MITT INCLUDING PROTECTION GUARD WITH TREAD FOR BASEBALL AND SOFTBALL | Dynasty Baseball, LLC | MORAN, KATHERINE M | 3732 | §103§112 | Non-Final OA | — | Pending | Dec 03, 2025 |
| 19252210 | COMPUTER-IMPLEMENTED METHOD FOR IDENTIFYING THE POSITION OF A HOLE OR A CRACK IN A DRILL STRING AND COMPUTER-READABLE STORAGE MATERIAL | Engineering Simulation And Scientific Software Ltda. | QUAIM, LAMIA | 3676 | §101§112 | Non-Final OA | — | Pending | Jun 27, 2025 |
| 19189953 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. | TRAN, ERIC | 1629 | §103 | Non-Final OA | 44d overdue | Pending | Apr 25, 2025 |
| 19181025 | HIGH TEMPERATURE CORROSION RESISTANT ORGANIC-INORGANIC HYBRID COATINGS | Ndsu Research Foundation | MCCLURE, CHRISTINA D | 1718 | §103 | Non-Final OA | — | Pending | Apr 16, 2025 |
| 19047044 | SEMq System for Identification, Determination, Characterization, and/or Quantification of Groundwater or Aquifers | G-Strata Spa | WALKER, CHRISTOPHER RICHARD | 3645 | §103 | Non-Final OA | — | Pending | Feb 06, 2025 |
| 19018493 | RETAIL INFORMATION DISPLAY SYSTEM | Sagenet LLC | GOODMAN, MATTHEW PARKER | 3637 | §103§112 | Non-Final OA | — | Pending | Jan 13, 2025 |
| 18858080 | CRYSTALLINE QUATERNARY SALTS OF 4-SUBSTITUTED TRYPTAMINES | Caamtech, Inc. | ANDERSON, JAMES D | 1629 | §102§112 | Non-Final OA | 44d overdue | Pending | Oct 18, 2024 |
| 18903459 | MECHANICAL VAPOR RE-COMPRESSOR HEAT PUMP FOR SEPARATING CO2 FROM WATER VAPOR IN TEMPERATURE-VACUUM SWING ADSORPTION CYCLES | Carbon Capture Inc. | JONES, CHRISTOPHER P | 1776 | §112 | Non-Final OA | — | Pending | Oct 01, 2024 |
| 18898755 | CRYSTALLINE 5-METHOXY-DIPROPYL TRYPTAMINE COMPOUNDS | Caamtech, Inc. | OH, TAYLOR V | 1625 | §103§112DP | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18897504 | MECHANICAL VAPOR RE-COMPRESSOR HEAT PUMP FOR SEPARATING CO2 FROM WATER VAPOR IN TEMPERATURE-VACUUM SWING ADSORPTION CYCLES | Carbon Capture Inc. | JONES, CHRISTOPHER P | 1776 | §112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18844280 | INHIBITORS OF FLI1 AND ERG | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18815064 | IONIZABLE LIPID NANOPARTICLES FOR IN UTERO mRNA DELIVERY | William Peranteau | PACKARD, BENJAMIN J | 1616 | §102§103§112DP | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18781180 | CRYSTALLINE BIS-MIPROCIN FUMARATE | Caamtech, Inc. | JACKSON, SHAWQUIA | 1626 | §112DP | Non-Final OA | — | Pending | Jul 23, 2024 |
| 18551119 | RISK DETERMINATION FOR A PROTHROMBOTIC THROMBOCYTOPAENIA | Universitaetsmedizin Greifswald | MUI, CHRISTINE T | 1797 | §101§102§112 | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18696645 | AUTONOMOUS ROBOT PLATFORM FOR PEST IDENTIFICATION AND CONTROL | Tecsoil Automacao E Sistemas S.A | AWORUNSE, OLUWABUSAYO ADEBANJO | 3662 | §103§112 | Final Rejection | 146d overdue | Pending | Mar 28, 2024 |
| 18695584 | STABILISING THE HUMAN SPINDLE BY KIFC1/HSET | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | BRETZ, COREY LANE | 1635 | §101§103§112Other | Non-Final OA | — | Pending | Mar 26, 2024 |
| 18611908 | DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE | Vistagen Therapeutics, Inc. | HUI, SAN MING R | 1627 | §101§103 | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18691986 | ASA-COPOLYMER COMPOSITIONS WITH INCREASED TRANSMITTANCE AND PROCESS FOR THE PREPARATION THEREOF | Ineos Styrolution Group GmbH | SALAMON, PETER A | 1759 | §103 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18688672 | METHOD FOR PRODUCING PRESERVED COLLAGENOUS CONNECTIVE TISSUE, COLLAGENOUS CONNECTIVE TISSUE, USES THEREOF AND KIT FOR IMPLANT IN TISSUES | Labcor Laboratorios Ltda | PENNINGTON, KATIE LEIGH | 1634 | §103§112DP | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18683854 | 3-CYCLOAMINO-INDOLE COMPOUNDS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. | MAHLUM, JONATHAN DAVIS | 1625 | §102§103§112Other | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18683842 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. | WEDDINGTON, KEVIN E | 1629 | §112Other | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18683846 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. | BELL, SARA ELIZABETH | 1625 | §102§112 | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18407432 | WIRELESS HEART TELEMETRY ELECTRODES AND PATIENT MONITORING SYSTEM | Jmad Creations, LLC | WINAKUR, ERIC FRANK | 3791 | §102§103§112 | Non-Final OA | — | Pending | Jan 08, 2024 |
| 18573732 | CROSS-LINKING POLYSACCHARIDE WITH FIBROIN AND USES OF THE OBTAINED MATERIAL | Merz Pharma GmbH & Co. Kgaa | ALDARONDO, DASIA ALI | 1647 | §102§103 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18569507 | HIGH CLARITY AND DUCTILE MOLDING COMPOSITION COMPRISING A SMMA COPOLYMER AND A SBC-BLOCK COPOLYMER | Ineos Styrolution Group GmbH | FOSS, DAVID ROGER | 1764 | DP | Non-Final OA | — | Pending | Dec 12, 2023 |
| 18563898 | HALLUCINOGEN-FATTY ACID COMBINATION | Mindset Pharma Inc. | RONEY, CELESTE A | 1612 | §112 | Non-Final OA | — | Pending | Nov 23, 2023 |
| 18562066 | ACRYLIC RUBBER FOR THERMOPLASTIC MATERIAL WITH GOOD LOW TEMPERATURE IMPACT STRENGTH | Ineos Styrolution Group GmbH | OLADAPO, TAIWO | §103 | Final Rejection | — | Pending | Nov 17, 2023 | |
| 18553868 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | BACHEM AG | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | — | Pending | Oct 04, 2023 |
| 18478427 | PRODUCTS AND METHODS FOR MONITORING ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR THERAPY | Orasure Technologies, Inc. | OGUNTADE, ELIZABETH BISOLA | 1677 | §103§112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18279290 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. | AULAKH, CHARANJIT | 1621 | §112 | Final Rejection | 5d | Pending | Aug 29, 2023 |
| 18279293 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. | SHTERENGARTS, SAMANTHA L | 1623 | §112 | Final Rejection | 48d | Pending | Aug 29, 2023 |
| 18360612 | PREPARING AND USE OF GLU-PLASMINOGEN FROM BLOOD FRACTIONS | Previpharma Consulting GmbH | XU, QING | 1656 | §103§112Other | Final Rejection | 9d | Pending | Jul 27, 2023 |
| 18262945 | CALCIUM HYDROXYAPATITE PARTICLES AND USE THEREOF | Merz North America, Inc. | MITCHELL, EDWIN COLEMAN | 1619 | §103 | Non-Final OA | — | Pending | Jul 26, 2023 |
| 18352677 | COMPOSITIONS CONTAINING KRATOM COMPOUNDS | Caamtech, Inc. | SPAINE, ROBERT FRANKLIN | 1655 | §101§103Other | Non-Final OA | 441d overdue | Pending | Jul 14, 2023 |
| 18348866 | CURABLE COATING COMPOSITIONS HAVING SUPERHYDROPHOBIC, ANTI-ICING, AND ANTI-CORROSION PROPERTIES | Ndsu Research Foundation | MILLER, BETHANY MACKENZIE | 1787 | §103§112 | Non-Final OA | — | Pending | Jul 07, 2023 |
| 18260711 | PROTECTED ALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES | Caamtech, Inc. | CHICKS, ASHLI ARIANA | 1626 | §102Other | Non-Final OA | — | Pending | Jul 07, 2023 |
| 18259683 | PLANT MATERIAL RECYCLING INOCULANT AND USES THEREOF | Imio Technologies, Inc. | STEINKE, SEAN JAMES | 1619 | §101§102§103§112Other | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18257639 | AMANITA MUSCARIA COMPOUNDS | Caamtech, Inc. | HOFFMAN, SUSAN COE | 1655 | §101§102§112 | Non-Final OA | 32d overdue | Pending | Jun 15, 2023 |
| 18265286 | 3-CYCLIC AMINE-INDOLE DERIVATIVES AS SEROTONERGIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | Mindset Pharma Inc. | LEE, CHIHYI NMN | 1628 | §103§112 | Final Rejection | 26d overdue | Pending | Jun 05, 2023 |
| 18310945 | PREVENTING DECOMPOSITION IN SODIUM CYANIDE COMPOSITIONS | Cyanco Corporation | NGUYEN, CAM N | 1736 | §102§112 | Non-Final OA | — | Pending | May 02, 2023 |
| 18299857 | STATIC MAGNETIC FIELD GENERATOR FOR TREATMENT OF CANCER | BRAIN & BEYONDS CO., LTD. | LANDEEN, BROGAN RANE | 3791 | §101§103 | Final Rejection | 2d overdue | Pending | Apr 13, 2023 |
| 18245053 | USE OF ACTIVE SUBSTANCES WITH ANTIVIRAL, ANTI MALARIAL, AND/OR MUCOLYTIC PROPERTIES IN THE TREATMENT OF VIRAL LUNG DISEASES INCLUDING COVID-19 BY SOFT MIST INHALER OR VIBRATION MESH TECHNOLOGY NEBULIZER THROUGH INHALATION ROUTE | Istanbul Universitesi Rektolugu | HAGHIGHATIAN, MINA | 1616 | §102§103§112 | Final Rejection | — | Pending | Mar 13, 2023 |
| 18178041 | COMPOSITION FOR IMPROVING THE APPEARANCE OF AGEING SKIN | Merz Pharma GmbH & Co. Kgaa | PURDY, KYLE A | 1611 | §103 | Non-Final OA | — | Pending | Mar 03, 2023 |
| 18105460 | CONJUGATES COMPRISING REVERSIBLE LINKERS AND USES THEREOF | Ascendis Pharma A/S | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §112 | Final Rejection | 34d | Pending | Feb 03, 2023 |
| 18161828 | MIXTURES AND FORMULATIONS | Camurus AB | CONIGLIO, AUDREA JUNE BUCKLEY | 1617 | §103DP | Non-Final OA | — | Pending | Jan 30, 2023 |
| 17997600 | THERMOPLASTIC POLYMER COMPOSITION WITH REDUCED MIGRATION OF STABILISERS | Ineos Styrolution Group GmbH | RODD, CHRISTOPHER M | 1766 | §103 | Non-Final OA | — | Pending | Oct 31, 2022 |
| 17904404 | DRG-MDM2-5 FOR USE AS A NOVEL MOUSE DOUBLE MINUTE 2 (MDM2) INHIBITOR | Istanbul Teknik Universitesi | MCANANY, JOHN D | 1625 | §112 | Final Rejection | — | Pending | Aug 17, 2022 |
| 17759974 | METHOD FOR INTRAOPERATIVELY OR POSTOPERATIVELY DETECTING IDH1 AND IDH2 GENE MUTATIONS IN GLIOMA TUMORS AND PRIMERS USED IN THIS METHOD | BAHCESEHIR UNIVERSITESI | MYERS, CARLA J | 1682 | §112 | Final Rejection | 187d overdue | Pending | Aug 02, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial80.1% of resolved applications prosecuted by Raphael Bellum Pllc were allowed, across 2,051 applications in USPTO records.
3.59 office actions per allowed application on average.
64 pending office actions as of October 2026, for 36 clients, before 61 examiners in 44 art units.
